Últimos Artículos de Journal of Neuroendocrinology
- Correction to abstract title “Efficacy and safety of [177Lu]Lu‐edotreotide vs. everolimus in patients with grade 1 or grade 2 gastroenteropancreatic neuroendocrine tumours: COMPETE phase 3 trial”
- Prognostic value of clinical parameters and exosomal lncRNA NEAT1_1 in MEN1‐related non‐functioning pancreatic neuroendocrine tumors
- Role of membrane estrogen receptor alpha on the negative feedback of estrogens on luteinizing hormone secretion
- The effects of feminization hormone therapy on the brain of transgender women: A hypothesis
- Early testosterone exposure during development advances myelination and affects neurogenesis of the vocal control motor path in male zebra finches (Taeniopygia guttata)
- Seasonal regulation of Tsh‐β, Dio2, Dio3, and GnRH‐I mRNA expressions in Eurasian tree sparrow (Passer montanus) under natural conditions
- Corticosteroid‐regulated gene transcription in SH‐SY5Y‐derived neurons: Insights into the mineralocorticoid and glucocorticoid receptor‐mediated response
- Comprehensive chemoanatomical mapping, and the gonadal regulation, of seven kisspeptin neuronal populations in the mouse brain
- The role of combined FDG and SST PET/CT in neuroendocrine tumors
- Developing a peripheral blood RNA‐seq based NETseq ensemble classifier: A potential novel tool for non‐invasive detection and treatment response assessment in neuroendocrine tumor patients receiving 177Lu‐DOTATATE PRRT
- Issue Information
- Peptide receptor chemoradionuclide therapy for neuroendocrine neoplasms: A systematic review
- Assessment of response to PRRT including anatomical and molecular imaging as well as novel biomarkers
- Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours
- Synthesis and characterisation of DOTA‐kisspeptin‐10 as a potential gallium‐68/lutetium‐177 pan‐tumour radiopharmaceutical
- PRRT in high‐grade digestive neuroendocrine neoplasms (NET G3 and NEC)
- Somatostatin receptor‐linked α‐particle therapy in neuroendocrine tumours
- Toxicity manifestations encountered in peptide receptor radionuclide therapy setting
- Role of neoadjuvant peptide receptor radionuclide therapy in unresectable and metastatic gastro‐entero‐pancreatic neuroendocrine neoplasms: A scoping review
- Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patients